Glecaprevir/Pibrentasvir · more major-labeled pairs than Buprenorphine
SPL labels Glecaprevir/Pibrentasvir + Buprenorphine as minor; Glecaprevir/Pibrentasvir 26 / Buprenorphine 28 in that band.
Mechanism on file: These drugs do not significantly change how the other works or how they are processed by the body.
FDA SPL severity: Minor
Glecaprevir/Pibrentasvir + Buprenorphine · SPL mechanism field
These drugs do not significantly change how the other works or how they are processed by the body.
Minor band excerpt · Glecaprevir/Pibrentasvir with Buprenorphine
↑= increase; ↓= decrease; ↔ = no effect 7.4 Medication-Assisted Treatment (MAT) for Opioid Use Disorder No buprenorphine/naloxone or methadone dosage adjustment is required when used concomitantly with MAVYRET.
Glecaprevir/Pibrentasvir · 3 major-labeled pairs (vs Buprenorphine's 0)
- Amlodipine minor
- Atorvastatin minor
- Buprenorphine/Naloxone minor
- Carbamazepine minor
Buprenorphine · 28 minor + 29 total pairs
- Alprazolam minor
- Buprenorphine (Pain) minor
- Buprenorphine/Naloxone minor
- Carbamazepine minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.